Assessing the Effects of Non-steroidal Anti-inflammatory Drugs on Antihypertensive Drug Therapy Using Post-Marketing Surveillance Database-Reference-Cited by-同舟云学术

Assessing the Effects of Non-steroidal Anti-inflammatory Drugs on Antihypertensive Drug Therapy Using Post-Marketing Surveillance Database

Published:2008 Issue:3 Volume:18 Page:119-124
ISSN:1349-9092
Container-title:Journal of Epidemiology
language:en
Short-container-title:Journal of Epidemiology

Author:

Ishiguro Chieko,Fujita Toshiharu,Omori Takashi,Fujii Yosuke,Mayama Takeshi,Sato Tosiya

Publisher

Japan Epidemiological Association

Subject

General Medicine,Epidemiology

Reference22 articles.

1. 1. Arellano FM. The withdrawal of rofecoxib. Pharmacoepidemiol Drug Saf 2005; 14: 213-7.

2. 2. Kuehn BM. FDA panel: keep COX-2 drugs on market: black box for COX-2 labels, caution urged for all NSAIDs. JAMA 2005; 293: 1571-2.

3. 3. CHMP review on non-selective non-steroidal anti-inflammatory drugs (NSAIDs) http://www.emea.europa.eu/htms/human/opiniongen/nsaids06.htm (accessed on January 22, 2008).

4. 4. Johnson AG, Nguyen TV, Day RO. Do nonsteroidal anti-inflammatory drugs affect blood pressure? A meta-analysis. Ann Intern Med 1994; 121: 289-300.

5. 5. White WB. Hypertension associated with therapies to treat arthritis and pain. Hypertension 2004; 44: 123-4.

Cited by 43 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. NSAIDs and Cardiovascular Toxicity;Reference Module in Biomedical Sciences;2024

2. The Effects of Pain and Analgesic Medications on Blood Pressure;Current Hypertension Reports;2022-06-15

3. The prescription patterns and safety profiles of oral non-steroidal anti-inflammatory drugs in China: an 8-year real-life analysis;Annals of Palliative Medicine;2021-02

4. Community prescribing of potentially nephrotoxic drugs and risk of acute kidney injury requiring renal replacement therapy in critically ill adults: A national cohort study;Journal of the Intensive Care Society;2020-02-13

5. Non-steroidal anti-inflammatory drug (NSAID) therapy in patients with hypertension, cardiovascular, renal or gastrointestinal comorbidities: joint APAGE/APLAR/APSDE/APSH/APSN/PoA recommendations;Gut;2020-01-14